SCHEMBL23536140

SCHEMBL23536140

COCS(=O)(=O)c1ccc(CBr)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.42
PSIP1 O75475 1/20 0.41
PLCG1 P19174 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MMP13 P45452 2/20 0.35
MMP8 P22894 1/20 0.35
GAA P10253 3/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
CA2 P00918 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20323522 0.83 LOX (0.49) PSIP1ALDH1A1KDM4ENPC1HPGD
SCHEMBL23554972 0.82 CA2 (0.53) MAOBPSIP1ALDH1A1KDM4EHPGD
SCHEMBL23536123 0.81 CA2 (0.52) MAOBPSIP1ALDH1A1KDM4ENPC1
SCHEMBL1939365 0.80 PLCG1 (0.59) MAOBPLCG1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1939488 0.79 PSIP1 (0.63) PSIP1PLCG1ALDH1A1SMN1; SMN2GAA
SCHEMBL23535962 0.78 MAOB (0.40) MAOBPSIP1ALDH1A1KDM4ENPC1
SCHEMBL29948486 0.78 MAOB (0.40) MAOBPSIP1ALDH1A1KDM4ENPC1
SCHEMBL23536115 0.78 MAOB (0.43) MAOBPSIP1ALDH1A1LMNAMAPT
SCHEMBL23555194 0.78 ALDH1A1 (0.57) MAOBALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL23370050 0.76 CA2 (0.52) MAOBALDH1A1SMN1; SMN2LMNAMMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 MAOB 2209/4885PSIP1 4432/4885PLCG1 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.